Horizon Pharma PLC (HZNP) is Reiterated by Mizuho to Buy, Lowers Price Target to $ 25

Horizon Pharma PLC (HZNP) was Reiterated by Mizuho to “Buy” while Lowering the Price Target of the company shares to $ 25 from a previous price target of $34 . Mizuho advised their investors in a research report released on May 3, 2016.

On the company’s financial health, Horizon Pharma PLC reported $0.63 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Feb 29, 2016. Analyst had a consensus of $0.60. The company had revenue of $244.50 million for the quarter, compared to analysts expectations of $240.81 million. The company’s revenue was up 135.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.27 EPS.

Horizon Pharma PLC closed down -0.06 points or -0.39% at $15.31 with 36,84,596 shares getting traded on Monday. Post opening the session at $15.45, the shares hit an intraday low of $14.75 and an intraday high of $15.57 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.

In a different news, on Dec 10, 2015, Jeffrey W Sherman (EVP and Chief Medical Officer) sold 4,456 shares at $20.00 per share price. According to the SEC, on Aug 21, 2015, Thomas Watkins (director) purchased 10,000 shares at $31.32 per share price. On Mar 17, 2015, Jeff Himawan (director) sold 554,564 shares at $22.47 per share price, according to the Form-4 filing with the securities and exchange commission.

Horizon Pharma plc formerly Vidara Therapeutics International Public Limited Company is a specialty biopharmaceutical company focused on identifying developing acquiring or in-licensing and commercializing differentiated products that address unmet medical needs. The Company markets a portfolio of products in arthritis inflammation and orphan diseases. The Company’s the United States marketed products are ACTIMMUNE (interferon gamma-1b) DUEXIS (ibuprofen/famotidine) PENNSAID (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) RAYOS (prednisone) delayed-release tablets and VIMOVO (naproxen/esomeprazole magnesium). The Company developed DUEXIS and RAYOS/LODOTRA has the United States rights to VIMOVO has the United States rights to ACTIMMUNE and has the United States rights to PENNSAID 2%.

Horizon Pharma PLC

Leave a Reply

Horizon Pharma PLC - Is it time to Sell?

Top Brokerage Firms are advising their investors on Horizon Pharma PLC. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.